ArticleHuman vaccines & immunotherapeutics2025
Successes, lessons learned and recommendations for the future: Experiences from the first year of Ontario's nirsevimab program for respiratory syncytial virus (RSV) prophylaxis in infants.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Post-licensure safety of nirsevimab from the Canadian National Vaccine Safety (CANVAS) network.Human vaccines & immunotherapeutics · 2026Article
- Respiratory Syncytial Virus-Related Hospitalizations Among Infants Receiving Nirsevimab.JAMA network open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At the conclusion of the 2024/2025 respiratory syncytial virus (RSV) season in Ontario, a panel of healthcare providers who were actively involved in the conduct of the province's first RSV prophylaxis program with nirsevimab in infants, assembled to discuss their experiences. The discussion was a follow-up to a larger pre-RSV season meeting held in June 2024 to develop recommendations supporting a universal prophylaxis program for infants in Ontario. The principal objective of the 2025 meeting was to identify components of the province's program that were successful, as well as those that posed barriers to nirsevimab uptake. A modified version of the World Health Organization's analytical framework for health systems was used to structure the discussion around five key programmatic building blocks: (1) governance and leadership, (2) funding and reimbursement, (3) logistics, demand and distribution, (4) awareness and education, and (5) surveillance and monitoring. A consensus was reached on updated recommendations to enhance the success of Ontario's nirsevimab program for future RSV seasons. These recommendations aim to ensure equitable access for all infants, achieve optimal uptake, and provide the best protection against RSV infection for Ontario's infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.